Trulive Medical Honored on Dual 2024 China MedTech Innovation Index Lists and Files IPO Prospectus

Dec 25, 2024 08:00 CST Updated 08:00

Trulive

Structural Heart Disease Device Developer

To continuously leverage the radiating and driving role of national-level innovation platforms, further stimulate innovation vitality, solidly promote the high-quality development of the high-performance medical device industry, and accelerate the development of new quality productive forces in China's medical equipment sector, the National Innovation Center for High-Performance Medical Devices has organized and launched the 2024 Medical Device Industry Innovation Ecosystem Insight Assessment. Since the assessment activity began in August, after more than three months of collection, preliminary evaluation, re-evaluation, expert review, and other multi-stage screening, Trulive Medical successfully made it to the list with outstanding performance."Top 100 Emerging Companies in the 2024 Medical Device Industry Innovation Index" and "2024 Medical Device Industry High-Value Consumables Field Innovation Index" dual rankings.

Trulive's appearance on the two lists this time not only represents high recognition of the company's dedication to the R&D of high-end medical devices, but also highlights the growing influence of Trulive in the industry.

Trulive will continue to uphold its original mission of shouldering the lives of hundreds of millions of patients, and constantly increase its exploration into unmet and unconquered blank areas in cardiovascular care. It aims to enhance its independent research and development capabilities as well as innovation abilities, providing safer, more effective, and accessible innovative solutions for patients in China and even globally, contributing to the advancement of human health.

-End-

Trulive

Jiangsu Trulive Medtech Co., Ltd. is a leading cardiovascular intervention platform company in China. The company focuses on cardiovascular disease areas with extremely high mortality and disability rates, where domestically produced products are still lacking. Its business comprehensively covers four major disease areas: heart valves, heart failure, peripheral, and coronary diseases, making it the first domestic platform-based high-end medical device company in China to fully cover these four key fields with substantial progress achieved in core products. With strong research and development capabilities and an experienced, complete operational team, Trulive Medtech has developed high-quality, proprietary medical devices and comprehensive solutions with independent intellectual property rights, filling the gap in China's high-end vascular intervention medical devices. It provides more advanced and diverse treatment options for Chinese doctors and patients, offering "Chinese solutions" and contributing "Chinese wisdom" in many细分 markets within the cardiovascular intervention field that have long been monopolized by imported products.

Scan the QR code to follow us

Business Cooperation | 021-50625001-8930

Email Address | vicky.z@trulive.cn